SUSTAINABILITY

SHORTENING AND DECARBONISING THE INHALATION SUPPLY CHAIN

INDUSTRIALISATION

SHORTENING AND DECARBONISING THE INHALATION SUPPLY CHAIN

Louise Righton examines the potential for reducing emissions across the pMDI supply chain, considering the localisation of suppliers to shorten supply chains as well as strong partnerships for developing novel, low-carbon alternatives to current high-emission pMDI manufacturing processes.

DRIVING SUSTAINABILITY IN DRUG DELIVERY DEVICE DESIGN AND MANUFACTURING

Martin Høier Thomsen

DRIVING SUSTAINABILITY IN DRUG DELIVERY DEVICE DESIGN AND MANUFACTURING

Martin Høier Thomsen discusses the need for the pharma industry to rise to the challenges of meeting its sustainability goals, explaining how MGS’ expertise and established practices to drug delivery device design and manufacture present a forward-thinking approach to achieving this aim.

A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

Dr Patrick Anquetil

Portal Instruments

A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors

In this exclusive interview with ONdrugDelivery’s Guy Furness, Dr Patrick Anquetil offers insight into the extensive waste involved in the self-injection market. He explains how pivoting from a model focused on fully disposable devices to reusable electromechanical autoinjectors could offer a more sustainable and cost-effective path forward.

SUSTAINABILITY IN DRUG DELIVERY: INNOVATIONS IN PLASTIC COMPONENTS AND CIRCULAR DESIGN

Edwin Van der Heul

ALBIS Distribution

SUSTAINABILITY IN DRUG DELIVERY: INNOVATIONS IN PLASTIC COMPONENTS AND CIRCULAR DESIGN

Edwin van der Heul considers the increasing regulatory pressure on manufacturers to deliver sustainable solutions in the medical device industry. This article explores these innovations and their impact on the future of drug delivery devices.

FIVE CRUCIAL COMPONENTS OF A SUCCESSFUL SUSTAINABLE PROCUREMENT STRATEGY

PCI Pharma Services

FIVE CRUCIAL COMPONENTS OF A SUCCESSFUL SUSTAINABLE PROCUREMENT STRATEGY

Ann Cartwright and Tim Hansen explain the five key components of PCI's sustainable procurement strategy to increase efficiency, meet regulatory demands and support business resilience and sustainability in the long term.

UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS

Stevanato Group

UNDERSTANDING PATIENT PREFERENCES FOR SUSTAINABLE ON-BODY DELIVERY SYSTEMS

Stevanato Group examines how semi-reusable, modular designs like its Vertiva 10 mL on-body delivery system can reconcile patient demands for ease of use with growing expectations for sustainability, sharing new UK preference data and lifecycle analysis that reveal significant waste and emissions reductions.

SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND

SUSTAINABLE GLP-1 DRUG DELIVERY: FUTURE-PROOFING THERAPY ADMINISTRATION FOR OBESITY AND BEYOND

Lorenzo Biasio and Gloria Skibba discuss the integration of Ypsomed’s Net Zero Program into its self-injection platforms. With the evolution of GLP-1 therapies and the exploration of higher-dose formulations, the demand for higher-volume autoinjectors is increasing; this article explains how Ypsomed has also applied its sustainability principles to larger-volume delivery.

The Transition to Lower-Global-Warming-Potential Propellants in pMDIs

The Transition to Lower-Global-Warming-Potential Propellants in pMDIs

Aptar Pharma’s Chris Baron discusses how the company has developed a new metering valve technology platform – ZEN30 Futurity™ – that is compatible with leading lower-GWP propellants. By collaborating with drug developers, regulators and the pMDI supply chain, Aptar Pharma aims to support the reduction of the CO₂ footprint of pMDIs while ensuring that the pharmaceutical industry’s strict regulatory requirements are met or exceeded.

THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION

THE PFAS PROBLEM: IMPROVING SUSTAINABILITY WITH NONWOVEN INNOVATION

Jack Eaton considers the current landscape for drug delivery and packaging, and how developments and research in nonwoven and fibrous materials can help businesses address the problem of per- and polyfluoroalkyl substances.

AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS

AI, DATA AND PARTNERSHIPS: THE BUILDING BLOCKS FOR MORE SUSTAINABLE CLINICAL TRIALS

Sas Maheswaran discusses how artificial intelligence, data and strategic partnerships can make clinical trials more sustainable – both financially and environmentally.

BIOPLASTICS IN DRUG DELIVERY: GETTING RID OF CRITICAL SUBSTANCES AND CARBON EMISSIONS

BIOPLASTICS IN DRUG DELIVERY: GETTING RID OF CRITICAL SUBSTANCES AND CARBON EMISSIONS

Julian Lotz introduces bio-based solutions for drug delivery devices, excelling in quality while meeting upcoming sustainability regulations, and explores the future of bioplastics in the healthcare sector.

IMPORTANCE OF PRE-COLOURED ABS IN INHALATION MEDICAL DEVICES

IMPORTANCE OF PRE-COLOURED ABS IN INHALATION MEDICAL DEVICES

Luca Chiochia discusses the vital role of coloured plastics in medical devices and how the use of pre-coloured, pre-tested solutions can provide not only a significantly reduced regulatory burden for device developers and manufacturers but also a higher quality end product, going on to explain how the company is approaching the critical subject of producing more sustainable polymers.

GLAUCOMA IN VIEW: IMPROVING PATIENT ADHERENCE WITH MULTIDOSE EYEDROPPERS FOR PRESERVATIVE-FREE SOLUTIONS

GLAUCOMA IN VIEW: IMPROVING PATIENT ADHERENCE WITH MULTIDOSE EYEDROPPERS FOR PRESERVATIVE-FREE SOLUTIONS

Zoë Davidson considers the impact of glaucoma on global health and the challenges presented by the increasing prevalence of this disease in the ageing global population, discussing how Novelia®, Nemera’s multidose eyedropper for preservative-free formulations, is well-positioned to address many of the challenges presented by glaucoma treatments, from ease of use to sustainability.

Interview: Sustainability at the Heart of Aptar Pharma’s Expansion

Audrey Chardonnet

Interview: Sustainability at the Heart of Aptar Pharma’s Expansion

Audrey Chardonnet discusses the centrality of sustainability to Aptar Pharma’s expansion strategy, going into detail on how, by improving its practices and investing in its infrastructure, the company works towards reducing the environmental impact of injectable drug delivery solutions manufacturing.

VERSATILITY, SUSTAINABILITY AND DIGITALISATION IN ONE SMART HANDHELD INJECTION PLATFORM

VERSATILITY, SUSTAINABILITY AND DIGITALISATION IN ONE SMART HANDHELD INJECTION PLATFORM

Leonard Chu discusses three trends in self-administration that are aligned with emerging smart devices – device versatility, sustainability and digitalisation – and the benefits offered by the Alcee injection platform.

NEXT-GENERATION AUTOINJECTORS: BALANCING PATIENTS, PHARMA, PAYERS AND PLANET

NEXT-GENERATION AUTOINJECTORS: BALANCING PATIENTS, PHARMA, PAYERS AND PLANET

David Latham, Matthew Allen and Charlie Dean use a case study of a reusable electromechanical autoinjector to outline the novel product development approach needed to achieve better outcomes for patients, pharma, payers and the planet.

REFORMULATING pMDIS WITH NEXT-GENERATION SUSTAINABLE PROPELLANTS

REFORMULATING pMDIS WITH NEXT-GENERATION SUSTAINABLE PROPELLANTS

Ross Errington and Simon Gardner, discuss sustainability and the reformulation of pMDIs with low-GWP propellants.

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

TRACE ANALYTICAL CONSIDERATIONS WHEN REFORMULATING pMDIS WITH NEXT-GENERATION LOW-GWP PROPELLANT SYSTEMS

Mark Parry, John McLaughlin and Tino Otte discuss the necessary studies required to understand the nitrosamine formation and leachables profiles of new pMDI propellants with lower global warming potentials as part of the pharmaceutical industry’s drive to reduce its emissions and environmental impact.

THE pMDI DILEMMA: MANAGING PATIENT NEEDS, HEALTH AND THE PLANET

THE pMDI DILEMMA: MANAGING PATIENT NEEDS, HEALTH AND THE PLANET

Nick Smalley discusses the balancing act involved in meeting patients’ therapeutic needs while protecting the planet when it comes to pMDI development.

PIONEERING PHARMACEUTICAL PACKAGING: A PUSH FOR DECARBONISATION AND CIRCULARITY

Philipp Ludihuser

PIONEERING PHARMACEUTICAL PACKAGING: A PUSH FOR DECARBONISATION AND CIRCULARITY

Philipp Ludihuser and Arne Kloke highlight how SCHOTT Pharma’s collaboration with customers and partners in the pharmaceutical industry reduces the carbon emissions from the production of vials, cartridges, ampoules and syringes, as well as introducing circular solutions to increase resource efficiency.

Interview with Bespak’s Louise Righton & Benedicta Bakpa

Interview with Bespak’s Louise Righton & Benedicta Bakpa

An increasing global incidence of respiratory diseases, such as asthma and COPD, is driving demand for therapies. Simultaneously, greenhouse gas emissions continue to rise, so the pharma industry must consider how to produce much-needed nasally delivered and orally inhaled medicines whilst minimising environmental impact. Louise Righton and Benedicta Bakpa discuss the many different aspects involved in driving sustainability in inhaled drug delivery – and the next steps.

PRIORITISING SUSTAINABILITY IN PHARMA

PRIORITISING SUSTAINABILITY IN PHARMA

Jessica Buday discusses how, in partnership with West Pharmaceutical Services, Corning’s Viridian glass vials are able to simultaneously improve the sustainability and efficiency of pharmaceutical fill-finish lines compared with traditional ISO glass vials, due to their reduced glass volume and proprietary external polymeric coating.

OPPORTUNITY THROUGH INNOVATION – ENVIRONMENTAL AND SOCIAL SUSTAINABILITY IN INJECTION DEVICES

Credence MedSystems

OPPORTUNITY THROUGH INNOVATION – ENVIRONMENTAL AND SOCIAL SUSTAINABILITY IN INJECTION DEVICES

John Merhige and Dan Thayer discuss how the successful implementation of ESG principles in the pharmaceutical sector requires innovation that allows sustainability to be seen as an opportunity rather than a burden. Furthermore, the authors present the case that improving on the social aspect of ESG is just as important as improving on the environmental side.

INTERVIEW with GLENN SVEDBERG

INTERVIEW with GLENN SVEDBERG

Glenn Svedberg engages in a wide-ranging discussion around the role and importance of sustainability in the drug delivery industry, and how Nolato Group has approached implementing this critical aspect of the modern industry landscape. Mr Svedberg considers how sustainability factors play into the relationship between CDMOs like Nolato and pharma companies, the importance of materials and how to drive forward sustainability goals within pharma and drug delivery.

Prev
1
2
3
4
…
7
Next

Top